Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174472 | 1.00 | MAPK1 (0.32) | MAPK1MEN1KMT2AESR1MAPT | |
| SCHEMBL12545158 | 1.00 | MAPK1 (0.32) | MAPK1MEN1KMT2AESR1MAPT | |
| SCHEMBL21997842 | 1.00 | MAPK1 (0.32) | MAPK1MEN1KMT2AESR1MAPT | |
| SCHEMBL31698149 | 0.82 | BRD4 (0.31) | — | |
| SCHEMBL5698891 | 0.81 | SMN1; SMN2 (0.42) | MAPK1MEN1KMT2APOLB | |
| SCHEMBL6204677 | 0.79 | ALDH1A1 (0.30) | ALDH1A1GLAHPGD | |
| SCHEMBL3275458 | 0.77 | ESR1 (0.30) | MEN1KMT2AESR1 | |
| SCHEMBL27146123 | 0.74 | ESR1 (0.35) | MEN1KMT2AESR1MAPTPOLB | |
| SCHEMBL22321254 | 0.74 | ESR1 (0.35) | MEN1KMT2AESR1MAPTPOLB | |
| SCHEMBL22286810 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2906537-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10092572-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAPK1 4408/4885MEN1 2339/4885KMT2A 1120/4885 |
| US-10092572-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | MAPK1 4408/4885MEN1 2339/4885KMT2A 1120/4885 |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | MAPK1 4510/4885MEN1 2024/4885KMT2A 2289/4885 |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAPK1 4408/4885MEN1 2339/4885KMT2A 1120/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | MAPK1 4408/4885MEN1 2339/4885KMT2A 1120/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | MAPK1 4408/4885MEN1 2339/4885KMT2A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.